id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2012-D-0880-0009,FDA,FDA-2012-D-0880,Draft Guidance for Industry on Generic Drug User Fee Amendments of 2012: Questions and Answers (Revision 1); Reopening of the Comment Period,Notice,General Notice,2013-11-27T05:00:00Z,2013,11,2013-11-27T05:00:00Z,2013-12-12T04:59:59Z,2016-11-18T14:46:02Z,2013-28392,0,0,090000648149c2b6
FDA-2012-D-0880-0006,FDA,FDA-2012-D-0880,Draft Guidance for Industry on Generic Drug User Fee Amendments of 2012: Questions and Answers (Revision 1); Availability,Notice,Notice of Availability,2013-09-10T04:00:00Z,2013,9,2013-09-10T04:00:00Z,2013-11-27T04:59:59Z,2016-11-18T14:44:33Z,2013-21891,0,0,09000064813ebe4c
FDA-2012-D-0880-0007,FDA,FDA-2012-D-0880,Draft Guidance for Industry on Generic Drug User Fee Amendments of 2012: Questions and Answers (Revision 1),Other,Guidance,2013-09-10T04:00:00Z,2013,9,2013-09-10T04:00:00Z,,2024-11-07T22:57:45Z,,1,0,09000064813eca54